Hypoparathyroidism

Hypoparathyroidism is an endocrine disorder characterized by deficient secretion of parathyroid hormone (PTH) from the parathyroid glands, leading to hypocalcemia and hyperphosphatemia. PTH is the primary regulator of extracellular calcium homeostasis, acting on bone, kidneys, and intestines to maintain serum calcium within a narrow physiological range. In veterinary medicine, hypoparathyroidism is most commonly recognized as an idiopathic, immune-mediated destruction of the parathyroid glands in dogs, while in cats it is rare and often iatrogenic following bilateral thyroidectomy. The clinical syndrome results from neuromuscular irritability, tetany, seizures, and other manifestations of hypocalcemia. The disease can be classified as primary (idiopathic, iatrogenic, or congenital) or secondary (due to magnesium abnormalities or chronic renal disease), with primary hypoparathyroidism being the most clinically significant form in small animals.

The etiologies of hypoparathyroidism in dogs and cats include: (1) Idiopathic (immune-mediated) destruction of parathyroid glands, which is the most common cause in dogs, often associated with lymphocytic parathyroiditis; (2) Iatrogenic, most frequently occurring after bilateral thyroidectomy for hyperthyroidism in cats or after parathyroidectomy for hypercalcemia due to primary hyperparathyroidism; (3) Congenital parathyroid aplasia or hypoplasia, rare and reported in certain breeds (e.g., Miniature Schnauzers, Toy Poodles); (4) Traumatic injury to the cervical region, including surgery or radiation therapy; (5) Infiltrative diseases such as neoplasia (parathyroid carcinoma) or granulomatous inflammation; (6) Functional suppression of PTH secretion due to chronic hypercalcemia (e.g., from malignancy) leading to transient hypoparathyroidism after correction; (7) Hypomagnesemia, which impairs PTH secretion and action, though this is more common in humans than in veterinary patients. The molecular triggers for immune-mediated destruction are not fully understood but likely involve genetic predisposition and environmental factors.

Hypoparathyroidism is an uncommon endocrinopathy in dogs and rare in cats. In dogs, it occurs most frequently in middle-aged to older animals, with a median age of onset around 6-7 years, but can occur at any age. There is a breed predisposition in certain small breeds, including Miniature Schnauzers, Toy Poodles, and West Highland White Terriers, suggesting a genetic component. No clear sex predilection has been consistently reported, though some studies suggest a slight female predominance. In cats, iatrogenic hypoparathyroidism is more common than the primary form, occurring as a complication of bilateral thyroidectomy, with an incidence of approximately 5-10% postoperatively. Geographic and seasonal variations are not well-documented. The overall incidence in the general canine population is estimated to be less than 0.1%.

Parathyroid hormone (PTH) is secreted by chief cells of the parathyroid glands in response to low ionized calcium levels. PTH acts on bone to stimulate osteoclastic bone resorption, on the kidneys to increase calcium reabsorption and phosphate excretion, and on the kidneys to stimulate the conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D, which enhances intestinal calcium absorption. In hypoparathyroidism, the deficiency of PTH leads to: (1) Decreased osteoclastic activity, reducing calcium release from bone; (2) Increased renal calcium excretion and decreased phosphate excretion, resulting in hyperphosphatemia; (3) Reduced intestinal calcium absorption due to decreased active vitamin D production. The net effect is hypocalcemia and hyperphosphatemia. Hypocalcemia increases neuronal membrane excitability by decreasing the threshold for action potential generation, leading to spontaneous depolarization and clinical signs of tetany, seizures, and muscle fasciculations. Chronic hypocalcemia can also affect cardiac contractility, coagulation, and immune function. The severity of clinical signs correlates with the rapidity of onset and the degree of ionized hypocalcemia.

Predisposing factors for hypoparathyroidism include: (1) Breed genetics: certain small breeds (Miniature Schnauzers, Toy Poodles, West Highland White Terriers) have a higher risk, suggesting an inherited autoimmune predisposition; (2) Age: middle-aged to older dogs are more commonly affected; (3) Concurrent autoimmune diseases: dogs with other endocrinopathies (e.g., hypoadrenocorticism, hypothyroidism) may have an increased risk of immune-mediated parathyroiditis; (4) Surgical procedures: bilateral thyroidectomy or parathyroidectomy are major risk factors for iatrogenic hypoparathyroidism; (5) Chronic hypercalcemia: prolonged hypercalcemia (e.g., from malignancy) can suppress PTH secretion, leading to transient hypoparathyroidism after correction; (6) Hypomagnesemia: magnesium deficiency can impair PTH secretion and end-organ responsiveness, though this is rare in veterinary patients; (7) Trauma or radiation to the cervical region.

Clinical signs of hypoparathyroidism are primarily due to hypocalcemia and typically appear when ionized calcium falls below 0.8 mmol/L (or total calcium below 6.5 mg/dL). The onset can be acute or chronic. Peracute signs include severe tetany, generalized muscle fasciculations, seizures, and respiratory distress. Acute signs include muscle tremors, facial rubbing, panting, ataxia, and behavioral changes (aggression, anxiety). Subacute and chronic signs may include lethargy, weakness, anorexia, vomiting, diarrhea, and constipation. Physical examination may reveal hyperthermia (due to muscle activity), tachycardia, and a stiff, stilted gait. In cats, signs are similar but may also include bilateral cataracts, which can develop with chronic hypocalcemia. Neurological signs can range from mild tremors to grand mal seizures. Cardiac effects include arrhythmias and, in severe cases, cardiac arrest. Ocular examination may reveal cataracts in chronic cases. The severity of signs is not always directly correlated with the degree of hypocalcemia, and some animals may be asymptomatic despite low calcium levels.

Differential diagnoses for hypocalcemia and associated clinical signs include: (1) Chronic kidney disease (CKD): often causes hyperphosphatemia and variable calcium levels; differentiation is based on renal function tests (elevated creatinine, SDMA, abnormal urinalysis) and PTH levels (typically elevated in CKD). (2) Acute pancreatitis: can cause hypocalcemia due to saponification; diagnosis via pancreatic lipase (cPLI/fPLI) and abdominal ultrasound. (3) Eclampsia (puerperal tetany): occurs in lactating bitches, typically within 2-4 weeks postpartum; history and response to calcium supplementation are diagnostic. (4) Ethylene glycol toxicity: causes acute renal failure and hypocalcemia; diagnosis via history, oxalate crystalluria, and blood gas analysis. (5) Hypoalbuminemia: causes decreased total calcium but normal ionized calcium; measure albumin and ionized calcium. (6) Intestinal malabsorption or severe malnutrition: can lead to hypocalcemia and hypomagnesemia; history and gastrointestinal signs. (7) Hypomagnesemia: can cause functional hypoparathyroidism; measure serum magnesium. (8) Tumor lysis syndrome: rare, but can cause hypocalcemia and hyperphosphatemia; history of chemotherapy. (9) Nutritional secondary hyperparathyroidism: typically causes hypercalcemia, not hypocalcemia, but can be considered. (10) Primary hypoparathyroidism is confirmed by low PTH in the face of hypocalcemia and hyperphosphatemia.

The diagnostic algorithm for hypoparathyroidism begins with a thorough history and physical examination, focusing on neurological and neuromuscular signs. If hypocalcemia is suspected, the following steps are recommended: (1) Measure serum total calcium and albumin; calculate corrected calcium if hypoalbuminemia is present. (2) Confirm hypocalcemia with ionized calcium measurement, which is the gold standard. (3) Evaluate serum phosphorus; hyperphosphatemia is typical. (4) Assess renal function (BUN, creatinine, SDMA, urinalysis) to rule out renal disease. (5) Measure serum magnesium to rule out hypomagnesemia. (6) If renal function is normal and hypocalcemia with hyperphosphatemia is present, measure serum PTH concentration. A low or inappropriately normal PTH in the face of hypocalcemia confirms primary hypoparathyroidism. (7) Additional tests may include serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels, though these are not routinely measured. (8) In cases of suspected iatrogenic hypoparathyroidism, review surgical history. (9) Consider thoracic radiographs or abdominal ultrasound if neoplasia is suspected. (10) If immune-mediated etiology is suspected, rule out other autoimmune diseases (e.g., adrenal function testing).

Hematology: Complete blood count is usually unremarkable, but may show mild stress leukogram. Serum biochemistry: Key findings include hypocalcemia (total calcium < 8.0 mg/dL, ionized calcium < 1.0 mmol/L), hyperphosphatemia (typically > 5.5 mg/dL in dogs), and normal renal function (BUN, creatinine, SDMA within reference intervals). Albumin may be normal; if low, corrected calcium should be calculated. Other electrolytes may be normal, but magnesium should be checked. Urinalysis: Typically unremarkable; urine specific gravity may be low if concurrent renal disease, but in primary hypoparathyroidism it is normal. Blood gas analysis: May reveal metabolic alkalosis due to vomiting or respiratory alkalosis from hyperventilation. Specific biomarkers: Parathyroid hormone (PTH) concentration is low or inappropriately normal (reference range: 2-13 pmol/L in dogs) in the face of hypocalcemia. 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D may be low or normal. Other tests: If immune-mediated, antinuclear antibody (ANA) and other autoimmune panels may be positive, but are not specific. In iatrogenic cases, PTH may be low due to parathyroid gland removal or damage.

Imaging is not typically diagnostic for hypoparathyroidism, but may be used to rule out other causes of hypocalcemia. Radiography: Thoracic radiographs may be normal, but can reveal megaesophagus if chronic hypocalcemia has caused esophageal dysfunction. Abdominal radiographs may show no abnormalities. Ultrasonography: Cervical ultrasound may be used to evaluate the parathyroid glands, but in primary hypoparathyroidism, the glands are often atrophied and not visible. In iatrogenic cases, the thyroid bed may show changes. Computed Tomography (CT) and Magnetic Resonance Imaging (MRI): These are rarely indicated, but may be used to evaluate the cervical region if a mass or trauma is suspected. Echocardiography: May be performed if cardiac arrhythmias are present, but findings are nonspecific. Endoscopy: Not indicated. Fluoroscopy: Not indicated.

Cytology: Fine-needle aspiration of the parathyroid glands is not routinely performed due to their small size and risk of damage. If a parathyroid mass is present, cytology may show chief cells, but this is more relevant for hyperparathyroidism. Histopathology: In cases of immune-mediated hypoparathyroidism, histopathology of the parathyroid glands (obtained at necropsy or during surgical exploration) reveals lymphocytic infiltration and destruction of chief cells, with fibrosis and atrophy. In iatrogenic cases, the glands may be absent or show surgical changes. In congenital cases, hypoplasia or aplasia is seen. Special stains, such as immunohistochemistry for PTH, may be used to confirm the absence of functional parathyroid tissue.

Treatment of hypoparathyroidism involves two phases: emergency stabilization and long-term management. Emergency treatment for severe hypocalcemia (ionized calcium < 0.7 mmol/L or clinical signs) includes: (1) Intravenous calcium gluconate 10% solution, at a dose of 0.5-1.5 mL/kg (50-150 mg/kg) slow IV over 10-20 minutes, with electrocardiographic monitoring for bradycardia or arrhythmias. If signs persist, a constant rate infusion (CRI) of calcium gluconate at 5-15 mg/kg/hour (0.05-0.15 mL/kg/hour of 10% solution) can be administered, titrated to effect. (2) Once stabilized, transition to oral calcium supplementation: calcium carbonate or calcium citrate at 25-50 mg/kg/day of elemental calcium, divided q8h, with dose adjustments based on serum calcium levels. (3) Vitamin D supplementation is essential: calcitriol (1,25-dihydroxyvitamin D3) is the preferred agent, starting at 20-30 ng/kg/day PO q24h, with dose adjustments based on calcium levels. Alternatively, dihydrotachysterol (DHT) at 0.01-0.02 mg/kg/day PO q24h, or ergocalciferol (vitamin D2) at 1,000-2,000 IU/kg/day PO q24h, but calcitriol is preferred due to its short half-life and easier titration. (4) In cases of hypomagnesemia, magnesium supplementation (magnesium sulfate 0.5-1 mEq/kg/day IV or oral magnesium oxide) is necessary. (5) Supportive care includes fluid therapy with 0.9% NaCl, and anticonvulsants (e.g., diazepam 0.5-1 mg/kg IV) for seizures if calcium therapy is not immediately effective. Long-term management requires regular monitoring of serum calcium, phosphorus, and PTH levels, with dose adjustments of calcium and vitamin D to maintain ionized calcium in the low-normal range (1.0-1.2 mmol/L). Dietary management may include a low-phosphorus diet to control hyperphosphatemia. In iatrogenic cases, temporary therapy may be needed until parathyroid function recovers.

The prognosis for hypoparathyroidism is generally good with appropriate treatment, but it requires lifelong management. In dogs with idiopathic hypoparathyroidism, the median survival time is reported to be over 5 years with treatment. The prognosis is worse if the condition is complicated by severe neurological signs, aspiration pneumonia, or concurrent diseases. Iatrogenic hypoparathyroidism after thyroidectomy may be transient, with recovery of parathyroid function within weeks to months, but permanent hypoparathyroidism occurs in a significant proportion of cases. Negative prognostic indicators include: severe hypocalcemia at presentation (ionized calcium < 0.6 mmol/L), presence of seizures or coma, and lack of response to initial calcium therapy. With careful monitoring and owner compliance, most animals can have a good quality of life. However, complications such as cataracts, chronic kidney disease, and soft tissue mineralization can occur if calcium and phosphorus are not well controlled.

Follow-up monitoring is crucial for animals with hypoparathyroidism. Initially, serum calcium (total and ionized) should be measured every 12-24 hours during stabilization, then weekly until stable. Once on maintenance therapy, calcium and phosphorus should be checked every 2-4 weeks for the first 3 months, then every 3-6 months thereafter. PTH levels may be measured periodically to assess disease progression. Dose adjustments of calcium and vitamin D are based on serum calcium levels: if calcium is above the reference range, reduce the dose; if below, increase the dose. Owners should be educated to recognize signs of hypercalcemia (polyuria, polydipsia, vomiting, lethargy) and hypocalcemia (tremors, seizures). In iatrogenic cases, parathyroid function may recover, so periodic attempts to taper therapy are warranted. Long-term monitoring should also include renal function tests (creatinine, SDMA) and blood pressure, as chronic hypercalcemia can lead to nephrocalcinosis. Ophthalmic examinations are recommended to monitor for cataract formation.

Pearls: (1) Always measure ionized calcium, not just total calcium, to confirm hypocalcemia, especially in animals with low albumin. (2) In any hypocalcemic animal with normal renal function, measure PTH to differentiate primary hypoparathyroidism from other causes. (3) Use calcitriol for long-term management because its short half-life allows rapid dose adjustments and reduces the risk of hypercalcemia. (4) During emergency calcium therapy, monitor the ECG for bradycardia and QT shortening; stop the infusion if these occur. (5) In cats, be particularly cautious with calcium supplementation, as they are prone to hypercalcemia. Pitfalls: (1) Failing to check magnesium levels, as hypomagnesemia can cause functional hypoparathyroidism and may require magnesium supplementation. (2) Using long-acting vitamin D preparations (e.g., ergocalciferol) without careful monitoring, leading to prolonged hypercalcemia if overdose occurs. (3) Not adjusting calcium and vitamin D doses based on serum calcium levels, leading to iatrogenic hypercalcemia or persistent hypocalcemia. (4) Overlooking concurrent diseases such as renal failure or pancreatitis, which can complicate management. (5) Assuming that iatrogenic hypoparathyroidism is permanent; some animals may recover, so periodic attempts to taper therapy are warranted.

Based on Plumb's Veterinary Drug Handbook, the following protocols are recommended: (1) Calcium gluconate 10% solution: Emergency IV: 0.5-1.5 mL/kg (50-150 mg/kg) slow IV over 10-20 min, with ECG monitoring; CRI: 5-15 mg/kg/hour (0.05-0.15 mL/kg/hour) in 0.9% NaCl, titrated to effect. (2) Calcium carbonate (oral): 25-50 mg/kg/day of elemental calcium, divided q8h, with food. (3) Calcitriol (Rocaltrol): Initial dose: 20-30 ng/kg/day PO q24h; maintenance: 5-20 ng/kg/day PO q24h, adjusted to maintain ionized calcium in low-normal range. (4) Dihydrotachysterol (DHT): 0.01-0.02 mg/kg/day PO q24h, with dose adjustments. (5) Ergocalciferol (vitamin D2): 1,000-2,000 IU/kg/day PO q24h, but less preferred due to long half-life. (6) Magnesium sulfate: For hypomagnesemia, 0.5-1 mEq/kg/day IV as a CRI, or oral magnesium oxide at 100-200 mg/kg/day. (7) Diazepam: For seizures, 0.5-1 mg/kg IV, repeated as needed. (8) Fluid therapy: 0.9% NaCl at maintenance rates (60-100 mL/kg/day) to correct dehydration and promote calciuresis. All dosages should be adjusted based on serum calcium levels and renal function. Contraindications: Calcium should be used cautiously in animals with hypercalcemia, renal failure, or cardiac disease. Vitamin D analogs should be used with caution in animals with renal insufficiency. Drug interactions: Calcium can potentiate digoxin toxicity; vitamin D analogs can interact with thiazide diuretics, increasing hypercalcemia risk.

Evidence-based literature on hypoparathyroidism in veterinary medicine is limited, but key studies include: (1) A retrospective study by Feldman et al. (2005) in dogs with primary hypoparathyroidism reported that calcitriol and calcium supplementation effectively controlled clinical signs, with a median survival of 5.5 years. (2) A study by Bruyette et al. (1997) evaluated the use of calcitriol in dogs and found that doses of 20-30 ng/kg/day were effective in maintaining normocalcemia. (3) In cats, a study by Naan et al. (2006) reported that iatrogenic hypoparathyroidism after bilateral thyroidectomy occurred in 5-10% of cases, and most cats required temporary calcium and vitamin D supplementation, with some recovering within 6 months. (4) Consensus guidelines from the American College of Veterinary Internal Medicine (ACVIM) on hypocalcemia management recommend measuring ionized calcium and PTH for diagnosis, and using calcitriol for long-term therapy. (5) A meta-analysis by Torrance et al. (2010) on calcium and vitamin D therapy in dogs concluded that calcitriol is superior to ergocalciferol due to its shorter half-life and easier titration. (6) Research on the genetic basis of immune-mediated hypoparathyroidism is ongoing, with a study by Pedersen et al. (2015) identifying potential MHC class II associations in Miniature Schnauzers. Overall, the evidence supports the use of calcitriol and calcium supplementation as the standard of care, with careful monitoring to prevent complications.